Palleon Pharmaceuticals Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 19
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $100M
Latest Deal Amount
  • Investors
  • 7

Palleon Pharmaceuticals General Information

Description

Developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 266 Second Avenue
  • 2nd Floor
  • Waltham, MA 02451
  • United States
+1 (857) 000-0000

Palleon Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Palleon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 16-Sep-2020 $100M 00000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 04-Oct-2017 000.00 000.00 000.00 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Palleon Pharmaceuticals’s complete valuation and funding history, request access »

Palleon Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view Palleon Pharmaceuticals’s complete cap table history, request access »

Palleon Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
James Broderick MD Co-Founder, Chief Executive Officer, President & Board Member
Li Peng Ph.D Chief Scientific Officer
Paul Crocker Ph.D Co-Founder & Scientific Advisor
John Hennessy Vice President, Operations & Finance
Carolyn Bertozzi Ph.D Co-Founder & Scientific Advisor
You’re viewing 5 of 6 executive team members. Get the full list »

Palleon Pharmaceuticals Board Members (15)

Name Representing Role Since
Deepa Pakianathan Ph.D Palleon Pharmaceuticals Board Member 000 0000
Eric Xiao Matrix Capital Management Board Member 000 0000
James Broderick MD Palleon Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Jayson Punwani Ph.D Self Board Member 000 0000
Karan Takhar Matrix Capital Management Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Palleon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Palleon Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Citadel (Hedge Fund) Hedge Fund Minority 000 0000 000000 0
Matrix Capital Management Hedge Fund Minority 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
SR One Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »